RxDoctor Payments Data

Jeremy Cook

Foot & Ankle Surgery · Cambridge, MANPI 1023221082

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,780 of the $4,390 with a category attached, or 86.1%. 8 manufacturers reported payments, led by Hologic Inc at 47.8% of the total. Reporting peaked in 2021 at $1,724 and has fallen 90.4% since, to $166 in 2025.

$4,390in general payments, 2019–2025

Across 20 payments — averaging $219.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Hologic Inc$2K
  • Paratek Pharmaceuticals, Inc.$2K
  • Stryker$404
  • Innovation Technologies Inc$80
  • Zimmer Biomet$44
  • Smith+Nephew$41
  • plus $40 from 2 others
$106,295in research payments, 2019–2025

Across 4 payments — averaging $26,574 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Smith+Nephew$106K

What the payments were for

  • Consulting fees$3,78086%
  • Food & beverage$61014%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,390 in reported general payments places this provider in the 70th percentile of 122 foot & ankle surgery providers in Massachusetts.

See all foot & ankle surgery providers in Massachusetts

Medicare billing

Part B allowed, 2024
$138,679
Medicare patients
363
Services billed
1,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium21$457
Meloxicam18$72

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Cambridge

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →